CFT-1946 is under clinical development by C4 Therapeutics and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData, Phase II drugs for Anaplastic Thyroid Cancer have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CFT-1946’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CFT-1946 is under development for the treatment of genetically defined drug-resistant BRAF mutant tumors including locally advanced or metastatic melanoma, melanoma, non-small cell lung cancer (NSCLC), anaplastic thyroid cancer and metastatic colorectal cancer. These are administered through oral route. It acts by targeting B-RAF (serine/threonine-protein kinase B-Raf). The drug candidates are developed based on TORPEDO platform (Target Oriented Protein Degrader Optimizer).
C4 Therapeutics overview
C4 Therapeutics is a pharmaceutical company. Its products are used for treating cancers such as multiple hematologic malignancies, non-Hodgkin’s lymphomas, multiple myeloma and neurological diseases and others. The company utilizes C4T TORPEDO 9, an integrated technology platform to advance drug design and target disease-relevant proteins for degradation. It develops a TAG, a chemical genetic system to understand the consequences of target protein degradation. The company partners with Biogen Inc, Calico LLC and Roche Holding AG to discover, develop and commercialize therapies for anti-aging, neurological diseases and cancer treatments. C4 Therapeutics is headquartered in Watertown, Massachusetts, the US.
For a complete picture of CFT-1946’s drug-specific PTSR and LoA scores, buy the report here.